{"lc": 1, "type": "constructor", "id": ["langchain", "schema", "document", "Document"], "kwargs": {"metadata": {"source": "/home/guanzhideng145/research/ip_portal/patent_kg/patents/124-US9,335,321(active).pdf"}, "page_content": "should:\n\n15\n\n20\n\n25\n\n30\n\n35\n\n40\n\n45\n\n50\n\n55\n\n60\n\n65\n\n(Epstein and Epstein, 2005; Goldsmith, 2004; Parng et al.,\n\ndrug discovery together with the corresponding toxicity test.\n\nThis invention relates to a 3-tier screening system using\n\nleast toxicity. In the first tier, the object is to identify quickly any agent\n\nlating agent and the agent will proceed to next tier. In second tier, the dose response relationship of the agent\n\ndeath and malformation, will still appear and the effect will be\n\nUS 9,335,321 B2\n\n3\n\n4\n\ntested are chosen in equal placement. Percentage of death and\n\nstronger as the concentration increases. Therefore, in this tier,\n\nthe NOAEC of the agent on teleost is determined. The pre\n\nmalformation in each concentration is determined and plotted\n\nin a graph to show the dose response relationship. A dose\n\nferred stage of embryos to be examined is 24 or 48 hpf.\n\nresponse curve is fitted to all the data points and the concen\n\nIn the third tier, it will be determined whether the agent at\n\ntration corresponding to the highest concentration at which\n\nthe level of NOAEC, instead of gross abnormalities, will\n\nthere are no statistically significant increase in the percentage\n\ninduce any adverse effect at the organ level and cellular level.\n\nof adverse effects between exposed group and control group\n\nTherefore, safety of an agent will be evaluated by mean of a\n\ncytotoxicity test, organ toxicity test and cardiotoxicity test. In\n\nis determined as NOAEC. This concentration level will then\n\naddition, angiogenic modulating activity will be tested at\n\nbe used in the third tier. If for any agent no NOAEC can be\n\nNOAEC. In this tier, visualization of intersegmental vessels is\n\ndetermined, it will be discarded from the testing.\n\n10\n\nby microangiography imaging technology in which fluores\n\nThe aim of the third tier is to find out any side effect of the\n\nagent at the concentration level not causing any gross adverse", "type": "Document"}}